Is Chromadex Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Chromadex Corp. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears undervalued based on its strong performance metrics, including a P/E ratio of 63, an EV to EBITDA ratio of 58.09, and an impressive ROCE of 1532.90%.
In comparison to peers, Chromadex Corp. has a higher P/E ratio than USANA Health Sciences, Inc. at 16.23 and LifeVantage Corp. at 14.81, which suggests that while it may seem expensive on a standalone basis, its growth potential is significant. Additionally, the PEG ratio of 0.07 indicates that the stock is undervalued relative to its expected growth. Over the past year, Chromadex has returned 113.08%, significantly outperforming the S&P 500's 14.08%, reinforcing the notion that the stock is positioned well for future growth despite recent volatility.